Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Lixisenatide (Adlyxin) vs Retatrutide
An educational, source-based comparison of Lixisenatide (Adlyxin) and Retatrutide — how each peptide works, what it's researched for, and what to know before going deeper.
Short-acting GLP-1 agonist focused on postprandial glucose.
Exendin-4 derivative with potent postprandial glucose-lowering effect via delayed gastric emptying and enhanced insulin response.
- Type 2 diabetes
- Postprandial hyperglycemia
- • FDA-approved.
- • GI side effects common.
A synthetic peptide that simultaneously agonizes GLP-1, GIP, and glucagon receptors. The glucagon component is hypothesized to add energy expenditure on top of the appetite suppression and insulinotropic effects of GLP-1/GIP.
- Obesity and weight loss (Phase 3)
- Type 2 diabetes
- NAFLD/MASH
- • Investigational; not FDA-approved (Phase 3 ongoing).
- • GI side effects common, similar to other incretin therapies.
- • Requires physician oversight.
Lixisenatide (Adlyxin) vs Retatrutide — Key differences
- Class: Lixisenatide (Adlyxin) is classified as GLP-1 Agonist · Metabolic, while Retatrutide is Metabolic · Incretin.
- Primary research focus: Lixisenatide (Adlyxin) — type 2 diabetes; Retatrutide — obesity and weight loss (phase 3).
- Tag: FDA-Approved · Metabolic vs Weight loss.